Why the study?
Do VKORC1 and CYP2C9 genetic variants influence anticoagulation-related outcomes in warfarin-treated patients?
Population
172 anticoagulation clinic patients followed from warfarin initiation
Comparison
Presence of VKORC1 and CYP2C9 genetic variants vs Patients without CYP2C9 variants or VKORC1…
Design
Cohort
Authors
Loading...
Warrants closer INR monitoring during warfarin initiation in variant carriers; extends observational pharmacogenetic data without supporting routine genotyping.
Do VKORC1 and CYP2C9 genetic variants influence anticoagulation-related outcomes in warfarin-treated patients?
Genetic variations in VKORC1 and CYP2C9 differentially influence warfarin anticoagulation outcomes, including time to stable dose and risk of overanticoagulation.
Meckley et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: